Literature DB >> 17872933

Remifentanil preconditioning confers delayed cardioprotection in the rat.

C K Yu1, Y-H Li, G T C Wong, T M Wong, M G Irwin.   

Abstract

BACKGROUND: Preconditioning with remifentanil (RPC) provides immediate cardioprotection in rats via all three types of opioid (OP) receptor. This study sought to investigate whether remifentanil also confers delayed cardioprotection via OP receptors.
METHODS: Male rats received preconditioning either by ischaemia (IPC; 5 min occlusion, 5 min reperfusion x 3) or with remifentanil (RPC; 1, 5, 10, and 20 microg kg(-1) min(-1), 20 min infusion). After 24 h, all animals were subjected to 30 min occlusion of the left coronary artery and 2 h of reperfusion. Subsequently, the time-course effect of RPC (10 microg kg(-1) min(-1), 20 min infusion) was determined at 12, 16, 24, 32, 36, and 48 h intervals, using the same experimental procedure. The effect of RPC (10 microg kg(-1) min(-1), 20 min infusion) and IPC in the presence of selective OP receptor antagonists was evaluated at the 24 h interval. Infarct size (IS), as a percentage of the area at risk (AAR), was determined.
RESULTS: Pre-treatment with remifentanil at 1, 5, 10, and 20 microg kg(-1) min(-1) significantly reduced the IS/AAR at 24 h with the maximum effect at 10 microg kg(-1) min(-1). Remifentanil at 10 microg kg(-1) min(-1) significantly reduced the IS at 12 h [32.5 (sd 9.1)%]; 16 h [26.1 (2.8)%]; 24 h [19.5 (5.0)%]; 32 h [31.2 (9.1)%]; and 36 h [36.4 (9.4)%] after drug administration. The maximal reduction in IS was seen at 24 h and the effect completely disappeared at 48 h [36.4 (9.4)%]. The protective effect of RPC was abolished or significantly attenuated by blockade of any of the three OP receptors with selective antagonists.
CONCLUSIONS: Like IPC, remifentanil produces delayed cardioprotection in anaesthetized rats 12-36 h after administration. The protective effect is mediated via all three OP receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872933     DOI: 10.1093/bja/aem261

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  6 in total

1.  Remifentanil preconditioning alleviating brain damage of cerebral ischemia reperfusion rats by regulating the JNK signal pathway and TNF-α/TNFR1 signal pathway.

Authors:  Yan Zhang; Yan-Wei Li; Ya-Xin Wang; Hong-Tao Zhang; Xiao-Mei Zhang; Yu Liang; Xiu-Shan Zhang; Wen-Sheng Wang; Hai-Gen Liu; Yi Zhang; Ling Zhang; Yu-Hua Zheng
Journal:  Mol Biol Rep       Date:  2013-11-05       Impact factor: 2.316

Review 2.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

3.  Morphine and remifentanil-induced cardioprotection: its experimental and clinical outcomes.

Authors:  Jin Mo Kim; Young Ho Jang; Jun Kim
Journal:  Korean J Anesthesiol       Date:  2011-11-23

4.  Hypercholesterolemic myocardium is vulnerable to ischemia-reperfusion injury and refractory to sevoflurane-induced protection.

Authors:  Yong Xu; Lei-Lei Ma; Chen Zhou; Fei-Jiang Zhang; Fei-Juan Kong; Wen-Na Wang; Ling-Bo Qian; Can-Can Wang; Xian-Bao Liu; Min Yan; Jian-An Wang
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

5.  Remifentanil preconditioning protects against hypoxia-induced senescence and necroptosis in human cardiac myocytes in vitro.

Authors:  Anna Lewinska; Jagoda Adamczyk-Grochala; Dominika Bloniarz; Beata Horeczy; Slawomir Zurek; Arkadiusz Kurowicki; Bogumila Woloszczuk-Gebicka; Kazimierz Widenka; Maciej Wnuk
Journal:  Aging (Albany NY)       Date:  2020-06-25       Impact factor: 5.682

6.  Effects of Remifentanil Preconditioning on Osteoblasts under Hypoxia-Reoxygenation Condition.

Authors:  Seung-Wan Baik; Bong-Soo Park; Yong-Ho Kim; Yong-Deok Kim; Cheul-Hong Kim; Ji-Young Yoon; Ji-Uk Yoon
Journal:  Int J Med Sci       Date:  2015-07-15       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.